<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616928</url>
  </required_header>
  <id_info>
    <org_study_id>110464</org_study_id>
    <nct_id>NCT00616928</nct_id>
  </id_info>
  <brief_title>Immunogenicity &amp; Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years</brief_title>
  <official_title>A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged ≥18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to
      characterize the immunogenicity &amp; safety of the investigation vaccination regimen of GSK
      1557484A vaccine given to adults aged ≥18 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)</measure>
    <time_frame>At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer &lt; 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)</measure>
    <time_frame>At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Solicited Local Symptoms.</measure>
    <time_frame>During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Solicited General Symptoms.</measure>
    <time_frame>During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration</time_frame>
    <description>Assessed solicited general symptoms were fatigue, headache, joint pain at other locations, muscle aches, shivering, sweating and temperature[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During a 21-day follow-up period for each vaccine administration, as well as overall (Day 0 through Day 84)</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 0 through Day 182 and through Day 379.</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Medically Attended Events (MAEs)</measure>
    <time_frame>From Day 0 through Day 182 and through Day 364.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serum Reciprocal HI Antibodies Against A/Indonesia/5/2005 Equal to or Above (≥) 1:10</measure>
    <time_frame>At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With A/Indonesia/5/05 Antibody Titers ≥ 1:10</measure>
    <time_frame>At Month 6 (Day 182) post Dose 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)</measure>
    <time_frame>At Month 6 (Day 182) after Dose 1</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer &lt; 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)</measure>
    <time_frame>At Month 6 (Day 182) after Dose 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum HI Antibodies Against A/Indonesia/5/05 (H5N1)</measure>
    <time_frame>At Month 6 (Day 182) after Dose 1</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was ≥ 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Vaccine Response to the Vaccine-homologous Virus and Drift Variant H5N1 Virus, as Assessed by Microneutralization Assays.</measure>
    <time_frame>At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
    <description>Virus antibody response rates were defined as the number of subjects with antibody titers at Day 42 ≥ 4-fold the pre-vaccination antibody titers. The 2 strains assessed were Flu A/Indonesia/5/05 and Flu A/Vietnam/1194/04.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1) as Assessed by Microneutralization Assays</measure>
    <time_frame>At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
    <description>Titers were expressed as Geometric Mean Titers (GMTs).</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">4561</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza A (H5N1) 18-64Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 18-64Y Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza A (H5N1) &gt;64Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &gt;64Y Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza A (H5N1) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pooled group of subjects aged &gt;18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pooled group of subjects aged &gt;18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza A (H5N1) 18-60Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 18-60Y Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza A (H5N1) &gt;60Y Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged &gt;60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &gt;60Y Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects aged &gt; 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted</intervention_name>
    <description>Two intramuscular injections at Days 0 and 21.</description>
    <arm_group_label>Influenza A (H5N1) 18-60Y Group</arm_group_label>
    <arm_group_label>Influenza A (H5N1) Group</arm_group_label>
    <arm_group_label>Influenza A (H5N1) &gt;60Y Group</arm_group_label>
    <arm_group_label>Influenza A (H5N1) 18-64Y Group</arm_group_label>
    <arm_group_label>Influenza A (H5N1) &gt;64Y Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two intramuscular injections at Days 0 and 21.</description>
    <arm_group_label>Placebo 18-60Y Group</arm_group_label>
    <arm_group_label>Placebo &gt;64Y Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_label>Placebo &gt;60Y Group</arm_group_label>
    <arm_group_label>Placebo 18-64Y Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female 18 years of age or greater at the time of the first vaccination.

          -  Written informed consent obtained from the subject.

          -  Among 18 to 49 year old subjects, good general health as established by medical
             history and clinical examination before entering into the study.

          -  Among subjects &gt; 49 years of age, stable health status within 1 month prior to
             enrollment.

          -  Access to a consistent means of telephone contact.

          -  Comprehension of the study requirements, ability to comprehend and comply with
             procedures for collection of short- and long-term safety data, expressed availability
             for the required study period, and ability and willingness to attend scheduled visits.

        Exclusion Criteria:

          -  Evidence of substance abuse or of neurological or psychiatric diagnoses which, even if
             clinically stable, are deemed by the investigator to render the potential
             subjectunable/unlikely to provide accurate safety reports.

          -  Diagnosed with cancer, or treatment for cancer, within 3 years.

          -  An oral temperature ≥37.8º C, or acute symptoms greater than &quot;mild&quot; severity on the
             scheduled date of first vaccination.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including
             history of human immunodeficiency virus infection.

          -  Receipt of systemic glucocorticoids within 1 month of study enrollment, or any other
             cytotoxic or immunosuppressive drug within 6 months of study enrollment.

          -  Any significant disorder of coagulation or treatment with Coumadin derivatives or
             heparin.

          -  Administration of any vaccines within 30 days before study enrollment.

          -  Previous administration of any H5N1 vaccine.

          -  Use of any investigational or non-registered product or planned participation in
             another investigational study within 30 days prior to study enrollment, or during the
             364 days following the first test article dose. Use of any investigational or
             non-registered product with immunosuppressive properties is exclusionary at any time
             during the trial.

          -  Receipt of any immunoglobulins and/or any blood products within 3 months of study
             enrollment or planned administration of any of these products during the study period.

          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of
             anaphylactic-type reaction to consumption of eggs; or a history of severe adverse
             reaction to a previous influenza vaccine.

          -  Known pregnancy or a positive urine beta-human chorionic gonadotropin test result
             prior to either vaccination.

          -  Lactating or nursing.

          -  Women of child bearing potential who lack a history of reliable contraceptive
             practices. The provision of this history does NOT replace the requirement to perform,
             and obtain negative results in pregnancy urine tests prior to treatments.

          -  Known use of an analgesic or antipyretic medication within 12 hours prior to first
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 6C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 4G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <results_first_submitted>December 19, 2013</results_first_submitted>
  <results_first_submitted_qc>December 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2014</results_first_posted>
  <disposition_first_submitted>May 20, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 28, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2009</disposition_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccines</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>human</keyword>
  <keyword>safety</keyword>
  <keyword>influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110464</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110464</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110464</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110464</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110464</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110464</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110464</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Influenza A (H5N1) 18-64Y Group</title>
          <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Placebo 18-64Y Group</title>
          <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>Influenza A (H5N1) &gt;64Y Group</title>
          <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>Placebo &gt;64Y Group</title>
          <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2304"/>
                <participants group_id="P2" count="768"/>
                <participants group_id="P3" count="1118"/>
                <participants group_id="P4" count="371"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2242"/>
                <participants group_id="P2" count="750"/>
                <participants group_id="P3" count="1101"/>
                <participants group_id="P4" count="364"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza A (H5N1) 18-64Y Group</title>
          <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Placebo 18-64Y Group</title>
          <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Influenza A (H5N1) &gt;64Y Group</title>
          <description>Influenza A (H5N1) &gt;64Y Group Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Placebo &gt;64Y Group</title>
          <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2304"/>
            <count group_id="B2" value="768"/>
            <count group_id="B3" value="1118"/>
            <count group_id="B4" value="371"/>
            <count group_id="B5" value="4561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="13.64"/>
                    <measurement group_id="B2" value="38.7" spread="13.58"/>
                    <measurement group_id="B3" value="71.9" spread="5.49"/>
                    <measurement group_id="B4" value="72.1" spread="5.41"/>
                    <measurement group_id="B5" value="49.5" spread="19.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1328"/>
                    <measurement group_id="B2" value="424"/>
                    <measurement group_id="B3" value="621"/>
                    <measurement group_id="B4" value="196"/>
                    <measurement group_id="B5" value="2569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="976"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="497"/>
                    <measurement group_id="B4" value="175"/>
                    <measurement group_id="B5" value="1992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer &lt; 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.</description>
        <time_frame>At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer &lt; 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.</description>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1571"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="396"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1427"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="293"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
        <time_frame>At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.</description>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1571"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="396"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1467"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="334"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
        <time_frame>During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Influenza A (H5N1) Group</title>
            <description>Pooled group of subjects aged &gt;18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>Pooled group of subjects aged &gt;18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited Local Symptoms.</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.</description>
          <population>The analysis was based on the Total Vaccinated cohort, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2267"/>
                <count group_id="O2" value="754"/>
                <count group_id="O3" value="1109"/>
                <count group_id="O4" value="368"/>
                <count group_id="O5" value="3376"/>
                <count group_id="O6" value="1122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2024"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="784"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="2808"/>
                    <measurement group_id="O6" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="287"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="351"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were fatigue, headache, joint pain at other locations, muscle aches, shivering, sweating and temperature[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.</description>
        <time_frame>During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, on subjects with symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Influenza A (H5N1) Group</title>
            <description>Pooled group of subjects aged &gt;18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>Pooled group of subjects aged &gt;18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited General Symptoms.</title>
          <description>Assessed solicited general symptoms were fatigue, headache, joint pain at other locations, muscle aches, shivering, sweating and temperature[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.</description>
          <population>The analysis was based on the Total Vaccinated cohort, on subjects with symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2266"/>
                <count group_id="O2" value="755"/>
                <count group_id="O3" value="1109"/>
                <count group_id="O4" value="368"/>
                <count group_id="O5" value="3375"/>
                <count group_id="O6" value="1123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="890"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="258"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="1148"/>
                    <measurement group_id="O6" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="932"/>
                    <measurement group_id="O2" value="249"/>
                    <measurement group_id="O3" value="247"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="1179"/>
                    <measurement group_id="O6" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain at other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="645"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="208"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="853"/>
                    <measurement group_id="O6" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1188"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="338"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="1526"/>
                    <measurement group_id="O6" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="563"/>
                    <measurement group_id="O6" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="362"/>
                    <measurement group_id="O6" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="156"/>
                    <measurement group_id="O6" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>During a 21-day follow-up period for each vaccine administration, as well as overall (Day 0 through Day 84)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2304"/>
                <count group_id="O2" value="768"/>
                <count group_id="O3" value="1118"/>
                <count group_id="O4" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unsolicited AEs Days 0-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="914"/>
                    <measurement group_id="O2" value="289"/>
                    <measurement group_id="O3" value="399"/>
                    <measurement group_id="O4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited AEs Days 0-84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1017"/>
                    <measurement group_id="O2" value="321"/>
                    <measurement group_id="O3" value="467"/>
                    <measurement group_id="O4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Day 0 through Day 182 and through Day 379.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2304"/>
                <count group_id="O2" value="768"/>
                <count group_id="O3" value="1118"/>
                <count group_id="O4" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with SAEs Days 0-182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with SAEs Days 0-379</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Medically Attended Events (MAEs)</title>
        <time_frame>From Day 0 through Day 182 and through Day 364.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Medically Attended Events (MAEs)</title>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2304"/>
                <count group_id="O2" value="768"/>
                <count group_id="O3" value="1118"/>
                <count group_id="O4" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with MAEs Days 0-182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="298"/>
                    <measurement group_id="O4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with MAEs Days 0-379</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="627"/>
                    <measurement group_id="O2" value="212"/>
                    <measurement group_id="O3" value="400"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serum Reciprocal HI Antibodies Against A/Indonesia/5/2005 Equal to or Above (≥) 1:10</title>
        <time_frame>At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-60Y Group</title>
            <description>Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-60Y Group</title>
            <description>Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;60Y Group</title>
            <description>Subjects aged &gt;60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;60Y Group</title>
            <description>Subjects aged &gt; 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serum Reciprocal HI Antibodies Against A/Indonesia/5/2005 Equal to or Above (≥) 1:10</title>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1488"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="479"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1391"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="410"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With A/Indonesia/5/05 Antibody Titers ≥ 1:10</title>
        <time_frame>At Month 6 (Day 182) post Dose 1</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo ˃ 64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With A/Indonesia/5/05 Antibody Titers ≥ 1:10</title>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer &lt; 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.</description>
        <time_frame>At Month 6 (Day 182) after Dose 1</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) reciprocal HI titer &lt; 1:10 and a post-vaccination (Day 42) reciprocal titer ≥ 1:40, or a pre-vaccination reciprocal HI titer ≥ 1:10 and at least a 4-fold increase in post-vaccination reciprocal titer against A/Indonesia/5/05 virus 21 days after the second dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.</description>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)</title>
        <time_frame>At Month 6 (Day 182) after Dose 1</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo &gt;64Y Group</title>
            <description>Subjects aged &gt;64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)</title>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables available at Month 6</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum HI Antibodies Against A/Indonesia/5/05 (H5N1)</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was ≥ 1:10.</description>
        <time_frame>At Month 6 (Day 182) after Dose 1</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Placebo ˃ 64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum HI Antibodies Against A/Indonesia/5/05 (H5N1)</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was ≥ 1:10.</description>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity - Month 6, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with a complete set of data concerning immunogenicity primary outcome variables at Month 6.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" lower_limit="31.0" upper_limit="42.2"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.8" upper_limit="6.5"/>
                    <measurement group_id="O3" value="44.8" lower_limit="33.3" upper_limit="60.4"/>
                    <measurement group_id="O4" value="5.4" lower_limit="4.6" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Vaccine Response to the Vaccine-homologous Virus and Drift Variant H5N1 Virus, as Assessed by Microneutralization Assays.</title>
        <description>Virus antibody response rates were defined as the number of subjects with antibody titers at Day 42 ≥ 4-fold the pre-vaccination antibody titers. The 2 strains assessed were Flu A/Indonesia/5/05 and Flu A/Vietnam/1194/04.</description>
        <time_frame>At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Vaccine Response to the Vaccine-homologous Virus and Drift Variant H5N1 Virus, as Assessed by Microneutralization Assays.</title>
          <description>Virus antibody response rates were defined as the number of subjects with antibody titers at Day 42 ≥ 4-fold the pre-vaccination antibody titers. The 2 strains assessed were Flu A/Indonesia/5/05 and Flu A/Vietnam/1194/04.</description>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with available data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/5/05</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam/1194/04</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1) as Assessed by Microneutralization Assays</title>
        <description>Titers were expressed as Geometric Mean Titers (GMTs).</description>
        <time_frame>At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)</time_frame>
        <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 18-64Y Group</title>
            <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) &gt;64Y Group</title>
            <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/Vietnam/1194/2004 (H5N1) and A/Indonesia/5/2005 (H5N1) as Assessed by Microneutralization Assays</title>
          <description>Titers were expressed as Geometric Mean Titers (GMTs).</description>
          <population>The analysis was based on the ATP cohort for analysis of immunogenicity, which included all evaluable subjects (meeting all eligibility criteria, complying with the procedures in the protocol, with no elimination criteria during the study) with available data.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Indonesia/5/05, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="19.9" upper_limit="25.3"/>
                    <measurement group_id="O2" value="52.4" lower_limit="39.2" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Indonesia/5/05, Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1450.6" lower_limit="1266.9" upper_limit="1660.9"/>
                    <measurement group_id="O2" value="631.1" lower_limit="444.5" upper_limit="896.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam/1194/04, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="25.7" upper_limit="34.9"/>
                    <measurement group_id="O2" value="94.4" lower_limit="68.4" upper_limit="130.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Vietnam/1194/04, Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.1" lower_limit="145.6" upper_limit="182.8"/>
                    <measurement group_id="O2" value="213.4" lower_limit="165.5" upper_limit="275.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were collected up to Day 182 and up to study end at Day 379. Unsolicited AEs were collected up to Day 20 and up to Day 84. Systematically-assessed symptoms were collected up to Day 6 post vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Influenza A (H5N1) 18-64Y Group</title>
          <description>Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Placebo 18-64Y Group</title>
          <description>Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Influenza A (H5N1) &gt;64Y Group</title>
          <description>Subjects aged &gt; 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, formulations A, B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>Placebo &gt;64Y Group</title>
          <description>Subjects aged &gt; 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Cholangitis suppurative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Left atrial dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Mountain sickness acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>HIV test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Diabetic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Hamartoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Lymph node cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Seminoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Tongue carcinoma stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Carotid artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Radiculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Renal vessel disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Biopsy liver normal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2024" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="784" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2024" subjects_at_risk="2267"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="754"/>
                <counts group_id="E3" subjects_affected="784" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="2267"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="754"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="241" subjects_at_risk="2267"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="754"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="890" subjects_at_risk="2266"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="258" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="932" subjects_at_risk="2266"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="247" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Joint pain at other location</sub_title>
                <counts group_id="E1" subjects_affected="645" subjects_at_risk="2266"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="208" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="1188" subjects_at_risk="2266"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="338" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="456" subjects_at_risk="2266"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="314" subjects_at_risk="2266"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="371"/>
              </event>
              <event>
                <sub_title>Temperature (Oral)</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="2266"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="755"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="1109"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="2304"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="768"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1118"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="371"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

